Applications and biological products of a long non-coding RNA

Abstract

The embodiment of the present disclosure relates to the application of a long-chain non-coding RNA as a molecular marker in the diagnosis or treatment of prostate cancer biological products, the long-chain non-coding RNA has the sequence shown in SEQ ID No.1, or SEQ ID No. 1 A transcribed sequence of the sequence shown in ID No.1, or a homologous sequence of the sequence shown in SEQ ID No.1 or a modified sequence of the sequence shown in SEQ ID No.1. Experiments conducted by the applicant have confirmed that the expression of long-chain non-coding RNA in the embodiment of the present disclosure is significantly higher than that in normal prostate tissue cells in the occurrence and development of prostate cancer.

Description

technical field [0001] The invention belongs to the technical field of genetic engineering, and in particular relates to a long-chain non-coding RNA and its application in diagnosing and treating prostate cancer. Background technique [0002] Prostate cancer is a malignant tumor with high incidence in men, and its mortality rate is second only to lung cancer. In recent years, with the changes in people's lifestyles and the aging of the population, the incidence of prostate cancer has shown an obvious upward trend. Statistics in Shanghai show that the incidence of prostate cancer has risen from 2.9 / 100,000 men in 1991 to The current 12.6 / 100,000 men have become one of the important diseases that seriously endanger the health of men in our country. [0003] Existing studies have shown that prostate cancer is a malignant tumor formed slowly under the joint action of multiple pathogenic factors, with significant tumor heterogeneity. Due to its slow disease progression, the dise...

AI Technical Summary

Problems solved by technology

[0004] At present, prostate-specific antigen (PSA) is mainly used clinically as a tumor marker for the screening, diagnosis, and postoperative tumor recurrence monitoring of prostate cancer patients. Clinical practice shows that PSA has obvious limitations, such as the lack of obvious tissue specificity. , benign prostate tissue can also secrete PSA, especially when prostatitis is more secreted, it cannot distinguish benign from malignant

Clinically, many patients choose to undergo prostate biopsy because their PSA is in the gray range (PSA 4-10ng / mL) and worry about the existence of malignant tumors, thus suffering unnecessary medical harm

Images